

### Subpart C—Labeling

#### § 332.30 Labeling of antifatulent drug products.

(a) *Statement of identity.* The labeling of the product contains the established name of the drug, if any, and identifies the product as an “antifatulent,” “antigas,” or “antifatulent (antigas).”

(b) *Indications.* The labeling of the product states, under the heading “Indications,” one or more of the phrases listed in this paragraph (b), as appropriate. Other truthful and nonmisleading statements, describing only the indications for use that have been established and listed in this paragraph (b), may also be used, as provided in § 330.1(c)(2) of this chapter, subject to the provisions of section 502 of the Federal Food, Drug, and Cosmetic Act (the act) relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act.

(1) (Select one of the following: “Alleviates or Relieves”) “the symptoms referred to as gas.”

(2) (Select one of the following: “Alleviates” or “Relieves”) (select one or more of the following: “bloating,” “pressure,” “fullness,” or “stuffed feeling”) “commonly referred to as gas.”

(c) *Exemption from the general accidental overdose warning.* The labeling for antifatulent drug products containing simethicone identified in § 332.10 and antacid/antifatulent combination drug products provided for in § 332.15, containing the active ingredients identified in § 331.11(a), (b), and (d) through (m) of this chapter are exempt from the requirement in § 330.1(g) of this chapter that the labeling bear the general warning statement “In case of accidental overdose, seek professional assistance or contact a poison control center immediately.” The labeling must continue to bear the first part of the general warning in § 330.1(g) of this chapter, which states, “Keep this and all drugs out of the reach of children.”

[39 FR 19877, June 4, 1974, as amended at 40 FR 11719, Mar. 13, 1975; 51 FR 16266, May 1, 1986; 51 FR 27763, Aug. 1, 1986; 52 FR 7830, Mar. 13, 1987; 61 FR 8838, Mar. 5, 1996]

#### § 332.31 Professional labeling.

(a) The labeling of the product provided to health professionals (but not to the general public) may contain as additional indications postoperative gas pain or for use in endoscopic examination.

(b) Professional labeling for an antifatulent-antacid combination may contain information allowed for health professionals for antacids and antifatulents.

### PART 333—TOPICAL ANTI-MICROBIAL DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

#### Subpart A [Reserved]

#### Subpart B—First Aid Antibiotic Drug Products

Sec.

- 333.101 Scope.
- 333.103 Definitions.
- 333.110 First aid antibiotic active ingredients.
- 333.120 Permitted combinations of active ingredients.
- 333.150 Labeling of first aid antibiotic drug products.
- 333.160 Labeling of permitted combinations of active ingredients.

#### Subpart C—Topical Antifungal Drug Products

- 333.201 Scope.
- 333.203 Definitions.
- 333.210 Antifungal active ingredients.
- 333.250 Labeling of antifungal drug products.
- 333.280 Professional labeling.

#### Subpart D—Topical Acne Drug Products

- 333.301 Scope.
- 333.303 Definitions.
- 333.310 Acne active ingredients.
- 333.320 Permitted combinations of active ingredients.
- 333.350 Labeling of acne drug products.

AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371, unless otherwise noted.

SOURCE: 52 FR 47322, Dec. 11, 1987, unless otherwise noted.